Treatment Mean paw volume ± SEM Mean ankle joint diameter ± SEM        
  7 DAY 14 DAY 21 DAY 28 DAY 21 DAY 28 DAY
DC 7.89 ± 0.18 7.93 ± 0.30 7.63 ± 0.25 6.75 ± 0.06 8.53 ± 0.07 8.49 ± 0.10
STD (P) 6.72 ± 0.21** 6.83 ± 0.25* 6.63 ± 0.13* 6.23 ± 0.11* 7.72 ± 0.22* 7.73 ± 0.22*
SV1 (P) (1μg/200gm) 7.04 ± 0.26* 6.9 ± 0.21* 6.64 ± 0.27* 6.24 ± 0.13* 7.72 ± 0.24* 7.65 ± 0.18*
SV2 (P) (2μg/200gm) 7.54 ± 0.11 6.91 ± 0.25* 6.63 ± 0.13* 6.15 ± 0.09** 8.66 ± 0.12 7.67 ± 0.22*
STD (T) 7.75 ± 0.08 8.18 ± 0.21 6.65 ± 0.21* 6.27 ± 0.13* 8.09 ± 0.18 7.66 ± 0.25*
SV1 (T) (1μg/200gm) 7.55 ± 0.14 8.32 ± 0.31 7.74 ± 0.38 6.23 ± 0.13* 8.32 ± 0.10 7.74 ± 0.08*
SV1 (T) (2μg/200gm) 7.51 ± 0.24 7.05 ± 0.21 6.6 ± 0.18* 5.92 ± 0.08** 8.25 ± 0.26 7.741 ± 0.16*
Values are expressed in mean ± SEM (n=6); *p<0.05, **p<0.01 vs. Disease control group, Data analysed by One-way ANOVA test followed by Dunnet’s multiple test for comparison. Treatment of various group are as follows, DC: Disease Control, STD: Indomethacin, SV: Scorpion Venom, P: Preventive treatment, T: Therapeutic treatment.
Table 2: Effect of SV (1 and 2 μg/200 gm) on paw volume and ankle joint diameter in FCA induced arthritis.